Millions of people with type 2 diabetes who take semaglutide, the active ingredient in Ozempic and Wegovy, can draw some reassurance from a large new study that found no link between the drug and neovascular age-related macular degeneration, a serious condition that can cause irreversible blindness. The research, conducted across multiple health system databases, adds clarity to an ongoing debate about whether GLP-1 receptor agonists carry hidden risks for eye health. The findings arrive after earlier research flagged a separate eye condition, nonarteritic anterior ischemic optic neuropathy, in patients prescribed the same drug class, raising broader concerns among clinicians and patients alike.
Why the AMD finding matters for semaglutide patients right now
Neovascular age-related macular degeneration, often called “wet AMD,” destroys central vision when abnormal blood vessels grow beneath the retina. It is one of the leading causes of severe vision loss in older adults, and people with diabetes already face elevated eye-disease risk. Any signal that a widely prescribed medication might accelerate wet AMD would have immediate consequences for prescribing decisions, insurance coverage, and patient willingness to start or continue treatment.
The new study, published in the journal Ophthalmology by the American Academy of Ophthalmology, used the OHDSI (Observational Health Data Sciences and Informatics) network to examine real-world records of adults with type 2 diabetes who were new users of semaglutide. The researchers found no statistically meaningful increase or decrease in risk of neovascular AMD among these patients. That neutral result is significant because it addresses a specific fear that had circulated in clinical circles since earlier studies raised questions about GLP-1 drugs and eye safety.
The distinction between different types of eye disease is central to understanding these results. Wet AMD is a degenerative retinal condition driven by abnormal vessel growth beneath the macula. Nonarteritic anterior ischemic optic neuropathy, or NAION, is a vascular event affecting blood flow to the optic nerve. These two conditions involve different anatomical structures and different biological mechanisms. That separation helps explain why semaglutide might show no signal for one condition while warranting continued scrutiny for the other. Researchers studying vascular versus degenerative retinal pathways will likely need to track each outcome in distinct patient groups rather than treating all serious eye diseases as a single category.
How the OHDSI network study and earlier NAION research fit together
The OHDSI network study drew on multiple databases to build a broad, population-level picture. By comparing new semaglutide users with matched comparators across several health systems, the observational design captured a wide range of patient backgrounds, treatment histories, and follow-up periods. The result, no statistically significant association in either direction between semaglutide use and wet AMD, provides a strong evidence base against the hypothesis that the drug accelerates this form of retinal degeneration.
That finding stands in contrast to earlier work on a different eye condition. A retrospective matched cohort study published in JAMA Ophthalmology examined the risk of NAION in patients prescribed semaglutide. That study helped trigger broader scrutiny of GLP-1 drugs and their potential effects on vision. NAION involves sudden loss of blood supply to the optic nerve and can cause permanent visual field deficits. The JAMA Ophthalmology research and related analyses identified through its citation trail prompted clinicians to pay closer attention to optic nerve events in patients using these medications.
Taken together, the two lines of evidence paint a more specific picture than early headlines suggested. The OHDSI results indicate that semaglutide does not appear to raise the risk of the degenerative macular form of serious eye disease. The NAION research, meanwhile, identified a signal worth tracking in a fundamentally different part of the eye’s vascular system. For patients and their doctors, this means the conversation about eye safety should focus on the type of condition rather than treating all vision risks as equivalent.
Open questions about semaglutide and long-term eye safety
Several gaps in the evidence remain. The OHDSI study used an observational design, which means it can identify associations but cannot prove causation in either direction. While the absence of a statistical signal is reassuring for wet AMD specifically, observational data cannot rule out small effects that might emerge over longer follow-up periods or in specific patient subgroups, such as those with pre-existing retinopathy or very long diabetes duration. The available primary sources do not report subgroup analyses by age, retinopathy status, or duration of semaglutide use.
Exact hazard ratios and patient-level data from the OHDSI analysis are not detailed in the published record summaries available for review. Direct statements from the study authors about how they handled confounding factors, such as prior eye exams or concurrent medications, are also absent from the primary materials. These details would help clinicians assess how well the findings apply to their own patient populations.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
